Cosette to add liquids to its portfolio with deal for 2nd G&W Labs plant 

Cosette Pharmaceuticals says it has acquired a second generics manufacturing facility from G&W Laboratories. (Image by Niek Verlaan from Pixabay)

Cosette Pharmaceuticals was formed last year when it picked up the dermatology business and a creams and topicals manufacturing plant of G&W Laboratories. Now, Cosette has gone back for another of G&W’s manufacturing facilities. 

Cosette has acquired G&W’s finished dose manufacturing plant in Lincolnton, North Carolina, that makes liquids. Details of the plant and terms of the deal were not disclosed. 

G&W is unrelated to the drugmaker GW Pharma that makes the cannabis-based drug Epidiolex. 

The G&W plant in South Plainfield, New Jersey, that Cosette got in its initial deal last December is allowed to manufacture extended topical and suppository products to treat skin and allergy problems. But with the acquisition of the North Carolina plant, Bridgewater, New Jersey-based Cosette says it will be able to grow its business in new areas. 

“The Lincolnton facility has an excellent track record of producing liquid pharmaceuticals along with other differentiated dosage forms, and operates as a contract manufacturer across multiple presentations for select business partners,” Cosette CEO Walt Kaczmarek said in a statement

Cosette was created when private equity investor Avista Capital Partners put up the money to buy G&W’s dermatology business, which included 35 self-labeled generic topical dermatology products sold in the U.S. and the 180,000-square-foot manufacturing facility in New Jersey.  It also does some contract manufacturing.  

G&W Labs is a family-owned business that works in the creams and topicals markets. It retains a plant in Pennsylvania.

Suggested Articles

Besides paying $729 million to settle notorious kickback allegations, Novartis has promised to put strict restrictions on its future speaker programs.

Pharma companies including Pfizer and Novartis paused advertising on Facebook for July to protest hate and disinformation on the platform.

CureVac and Tesla are teaming up to produce the German vaccine maker's molecular RNA printers, Tesla CEO Elon Musk tweeted Thursday.